GLIXOV: GLIX5 for Eggstokkreft_Skattefunn_2024

Offentlig prosjektsammendrag

Cancer is the second-leading cause of death globally, posing a major health crisis. Current therapies benefit only a small fraction of cancer patients, leading to significant healthcare costs on ineffective treatments. Ovarian cancer (OC) remains largely incurable, with only modest survival improvements, highlighting the urgent need for new strategies. Hemispherian’s novel drug, GLIX5, targets an unrecognized DNA pathway with exceptional anti-tumor efficacy. Co-developed with a sensitivity predictive biomarker (SPB), GLIX5 offers a personalized treatment approach. It has shown promising efficacy across various cancers, suggesting broader potential. Our project advances GLIX5’s preclinical development, explores other indications through an SPB-driven strategy, and establishes a scalable, cost-efficient CMC process. This aims to deliver smarter, targeted interventions, reducing unnecessary costs and offering OC patients more time with loved ones.